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Fibril in senile systemic amyloidosis is derived from
normal transthyretin
(prealbumin/primary structure)
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ABSTRACT The amyloid fibril in senile systemic amyloi-
dosis (SSA), like that of familial amyloidotic polyneuropathy,
is derived from transthyretin (TTR). SSA, however, is a
common disease, affecting to some degree 25% of the popula-
tion >80 years old. In familial amyloidotic polyneuropathy, the
amyloidogenesis has been considered to depend on point mu-
tations leading to TTR variants. We show that the TTR
molecule in SSA, on the other hand, has a normal primary
structure. Factors other than the primary structure of TTR
must therefore be important in the pathogenesis of TTR-
derived amyloid.
The amyloid fibril contains as a major constituent low mo-
lecular weight proteins that vary in nature between different
types of amyloid (1). Since the original description by Costa
et al. (2) that transthyretin (TTR) (prealbumin) is a main
constituent in the Portuguese type familial amyloid, many
other forms of familial amyloidosis have been shown to have
TTR as a major subunit protein. Recent studies have revealed
that the hereditary factor in the familial amyloidosis is a point
mutation in the TTR gene, leading to an amino acid substi-
tution. Several such mutations, each linked to a specific type
of amyloid disease, have now been demonstrated. The most
widely known amino acid substitution in the TTR molecule is
methionine for valine at position 30, found in the Portuguese,
Swedish, and Japanese types of familial amyloidosis (3-6).
The most common systemic amyloidosis is senile systemic
amyloidosis (SSA), earlier called senile cardiac amyloidosis
(7, 8). SSA has been shown to affect --25% of persons >80
years old (8), with deposits in many organs. It is usually a
benign disease without symptoms. Some individuals, mainly
men, are more severely affected with heavy deposits in the
myocardium, sometimes giving rise to cardiomegaly and
congestive heart failure (7, 9, 10).
Previous studies have shown that a major constituent ofthe
fibrils in SSA is derived from TTR (11, 12). A major question
in the understanding of the pathogenesis of the TTR-derived
amyloidoses is whether or not an amino acid substitution is
a prerequisite for formation of amyloid fibrils. In previous
partial characterization of the TTR in three patients with
SSA, no deviation from the normal sequence was found (13).
However, it has recently been claimed that SSA is a hered-
itary disease with late onset (14). In the present study, we
have characterized the TTR molecule purified from the
amyloid fibrils from a patient with typical SSA, and no amino
acid substitution was found.
MATERUALS AND METHODS
Heart tissue from one patient (patient 34) with typical SSA
was frozen at -20°C. The patient was a male who died when
he was 92 years old. Unexpectedly, a large diffusely amyloid-
infiltrated heart was found at autopsy. Microscopic analysis
revealed small amyloid deposits in many organs.
Purification of Amyloid Fibril Proteins. Amyloid fibrils
were extracted (15) from heart ventricles by sequential ho-
mogenization 10 times in 0.15 M NaCl, followed by homog-
enization three times in distilled water. After centrifugation
at 20,000 rpm (Beckman JA 20 rotor), most amyloid was
found in the pellet material, which was lyophilized and used
in the present studies.
Amyloid fibrils were defatted in chloroform/methanol (2:1)
and treated with 6 M guanidine hydrochloride in 0.1 M
Tris-HCl (pH 8.0) without reduction for 48 hr at room
temperature. The material was then centrifuged and the
supernatant was applied to a Sepharose CL-6B column,
which was eluted with 5 M guanidine in distilled water. This
process resulted in a typical pattern with a fairly small V.
peak, followed by a wide area (designated fraction A) with
increased optical density without distinct peaks, and finally
an asymmetric late retarded protein peak (designated fraction
B) (Fig. 1). The two fractions were dialyzed separately
against deionized water and lyophilized. Previous experi-
ments (13-15) have shown that both full-length TTR (called
TTR-like protein) and TTR fragments occur in the fibrils in
SSA. Under nonreducing conditions, fraction B consists
mainly of cysteine-lacking TTR-derived protein fragments,
while the TTR-like amyloid fibril protein is eluted in fraction
A (13).
For purification ofTTR-like protein, material from fraction
A was dissolved in 6 M guanidine hydrochloride/0.1 M
Tris-HCl buffer, pH 8.0, containing 0.1 M dithiothreitol and
was stirred for 2 hr at room temperature. Dithiothreitol was
removed by gel filtration through a Sephadex G-25 column
(0.9 x 10 cm) and the protein solution was then applied to a
Thiopropyl Sepharose CL-6B column (1.6 x 10 cm), equili-
brated with 4.5 M guanidine hydrochloride/0.1 M Tris'HCl,
pH 8.0 (13). The column was rinsed with the guanidine
solution and finally eluted with the equilibration solution,
now containing 25 mM L-cysteine. The eluted protein mate-
rial was dialyzed against deionized water and lyophilized.
Further purification was obtained by gel filtration through a
Sephacryl S-200 HR column (0.9 x 60 cm) equilibrated and
eluted with 5 M guanidine hydrochloride in distilled water.
Fraction B was used for further purification of cysteine-
lacking TTR fragments. Lyophilized protein (1 mg/ml) was
dissolved in 5 M guanidine hydrochloride in water and
injected into an LKB HPLC unit connected to a Vydac 214
TPS column. Proteins were eluted with a 0-70o linear
gradient of acetonitrile in 0.1% trifluoroacetic acid and the
effluent registered at 224 nm.
Abbreviations: TTR, transthyretin; SSA, senile systemic amyloido-
sis; BNPS-skatole, 3'-bromo-3-methyl-2-(2-nitrophenylsulfenyl)in-
dolamine.
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FIG. 1. The gel filtration elution profile of amyloid fibrils dis-
solved in guanidine hydrochloride and run on a Sepharose CL-6B
column. Fractions in A and B were pooled separately for the
purification of TTR-like material and TTR-derived fragments, re-
spectively.
Electrophoresis. SDS/PAGE was performed as described
(16).
Amino Acid Analysis. TTR-derived polypeptides were hy-
drolyzed in 6 M HCl and quantitated by amino acid analysis
using a Biotronik Wissentschaftlich Gerate, Frankfurt am
Main, F.R.G. LC 5000 automatic amino acid analyzer (13).
N-Terminal Analysis. The polypeptides were tested for
homogeneity and further analyzed by Edman degradation
using a model 477A automatic sequence analyzer from Ap-
plied Biosystems, with an on-line 120 A PTH amino acid
analyzer (13).
Fragmentation. Polypeptides were cleaved with cyanogen
bromide (17) and 3'-bromo-3-methyl-2-(2-nitrophenyl-
sulfenyl)indolamine (BNPS-skatole) (18). Digestion with en-
doproteinase Asp-N, obtained from Boehringer Mannheim,
was performed with SDS-treated polypeptide as described by
Drapeau (19).
Purification of Peptides. Peptides were purified on a C18
reversed-phase column 218 TP54 (Vydac, CA). A 45-min
linear gradient from 0%6 to 80o ofsolvent B was used at a flow
rate of 1.0 ml/min (20). Solvent A was 0.1% trifluoroacetic
acid in water, and solvent B was 30%6 solvent A in acetoni-
trile.
phase column. Peptide materials obtained from single peaks
were taken for N-terminal analyses. The results confirmed
and established the sequences of positions 18-35, 38-41,
42-60, 63-73, 74-88, 89-92, 92-98, and 99-127. The amino
acid residues in positions 17, 42, and 62 could not be verified
because of background interference. With the partial amino
acid sequences of the TTR-derived fragments (see below),
the full sequence of the amyloid TTR molecule was obtained
(Fig. 2). No amino acid substitution was found.
Amino Acid Sequence Analysis of TTR-Derived Fragments.
Reversed-phase HPLC on a C4 column of the late retarded
peak proteins from fraction B, obtained in the first gel
filtration, resulted in many closely eluted peaks, which were
purified by rerunning in HPLC. Characterization by N-
terminal analyses showed that fragments started in positions
46, 49, and 52 of TTR (Fig. 2). Positions 46-78 were estab-
lished. The amino acid sequence in this region was identical
to that reported for TTR (22, 23).
DISCUSSION
All TTR-derived amyloid fibril proteins that have been stud-
ied with complete amino acid sequence analysis have shown
amino acid substitutions (3-6, 24-29). Such substitutions
have therefore been considered to be the primary defect in
the amyloidogenesis involving TTR. Regarding the very high
frequency of SSA, amino acid substitutions in the TTR in all
cases is unlikely, however. The present study shows that
TTR with normal primary structure can also make up amyloid
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Purification and Analysis ofa TTR-Like Molecule. Previous
studies have shown that the TTR-like protein in the amyloid
fibrils in SSA and familial amyloidotic polyneuropathy of
Swedish type seems to be covalently bound (13, 21). This
characteristic made it possible to purify the TTR molecule by
initial gel filtration without reduction followed by covalent
chromatography and subsequent gel filtration ofthe cysteine-
containing material. In this way, we obtained TTR-like
protein that was essentially free from TTR fragments.
N-terminal sequence analysis revealed a ragged N termi-
nus with species starting in positions 1, 2, 3, 4, 5, 6, and 7 of
TTR. The contents ofthese species decreased gradually from
25% (position 1) to 8% (position 7). The initial yield was
=20%, which is within the expected range when working with
lower concentrations of proteins. The TTR sequence to
position 14 was confirmed. Cyanogen bromide cleavage of
the protein resulted in a free N terminus starting in position
14 of TTR. Thirty-two degradation cycles confirmed posi-
tions 14-40 and 43-45. Positions 41 and 42 could not be
established. The material left on the glass fiber membrane
after 32 degradation cycles was then used for cleavage with
BNPS-skatole and taken directly back to the sequencer for
analysis. Nineteen degradation cycles confirmed positions
43-51 and 82-98.
TTR-like protein was also digested with endoproteinase
Asp-N and the peptides were separated on a C18 reversed-
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FIG. 2. The amino acid sequence (single-letter code) of an
amyloid protein derived from TTR in patient 34. The sequence is
identical to that of normal TTR but a large portion of the TTR-like
protein started in positions 2-7. TTR fragments started in positions
46, 49, and 52 and constituted a considerable part of the amyloid
fibrils. The sequence was obtained by studies of the whole TTR-like
protein (TTR-L), TTR fragments occurring in the fibrils (Fl, F2, and
F3), and peptides resulting from cleavage with cyanogen bromide
(CB), endoproteinase Asp-N (PAS), and BNPS-skatole (BNPS). No
overlapping between PAS7 and PAS8 was obtained. Parentheses
indicate not fully identified amino acid residues.
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fibrils. Mechanisms other than amino acid substitutions must
therefore be important in fibrillogenesis in TTR amyloidosis.
Cardiomyopathy is the main hallmark ofadvanced SSA (7,
9, 10). Forms of TTR-derived familial amyloidosis in which
cardiomyopathy predominates in the clinical picture also
exist. One such form is the Danish amyloidotic cardiomyo-
pathy, where a methionine for valine substitution in position
111 of TTR has been recently shown (28). An isoleucine for
valine substitution at position 122 has recently been found in
several patients with amyloidotic cardiomyopathy (14, 30-
32). It has been claimed that these patients suffer from SSA;
however; this conclusion can be questioned since at least one
of them was much younger (68 years old; ref. 30) than most
patients with SSA. In our material, SSA with advanced
cardiomyopathy is almost exclusively observed in individu-
als >80 years old (ref. 7; B.J. and P.W., unpublished obser-
vations). Therefore, amyloidosis with substitution of isoleu-
cine for valine in position 122 should be regarded as a
previously unknown form of familial amyloidosis. In a pre-
vious study of another patient (HL) with SSA, in which a
partial amino acid sequence analysis of the amyloid subunit
protein was performed, no substitution at position 122 was
seen (11).
An interesting finding in SSA and other forms of TTR-
derived amyloid is the occurrence of T'R fragments in the
fibrils (13, 21). In many cases of SSA, as well as in some
patients with Swedish familial amyloidotic polyneuropathy,
such fragments predominate over the full-length TTR mole-
cules (6, 13, 21). This fragmentation is not random, since
cleavage has been reported predominantly at positions 46, 49,
and 52 (13, 28). In SSA and other TTR-derived amyloid
forms, it is possible that cleavage in the TTR molecule
precedes the amyloid fibril formation. This process might
expose hidden sequences that are prone to aggregate. An-
other possibility is that cleavage takes place after the fibril
has formed. The region with positions 46-52 is in the periph-
ery of the TTR tetramer (33) and is possibly most easily
attacked by enzymes. A finding that may indicate that
proteolysis is a secondary event is that the proportion of
uncleaved TTR in the fibrils varies greatly (unpublished
observation).
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